Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,259 INR | +0.80% | +0.59% | +16.11% |
06-05 | Hindalco-owned Novelis delays US IPO; shares slide | RE |
05-27 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
Sales 2024 | 290B 3.47B 4.77B | Sales 2025 * | 317B 3.79B 5.21B | Capitalization | 732B 8.76B 12.04B |
---|---|---|---|---|---|
Net income 2024 | 31.73B 380M 522M | Net income 2025 * | 39.08B 468M 643M | EV / Sales 2024 | 2.2 x |
Net cash position 2024 * | 18.34B 220M 302M | Net cash position 2025 * | 24.56B 294M 404M | EV / Sales 2025 * | 2.23 x |
P/E ratio 2024 |
20.1
x | P/E ratio 2025 * |
18.7
x | Employees | 23,451 |
Yield 2024 * |
0.34% | Yield 2025 * |
0.4% | Free-Float | 47.93% |
Latest transcript on Aurobindo Pharma
1 day | +0.78% | ||
1 week | +0.59% | ||
Current month | +6.15% | ||
1 month | +6.88% | ||
3 months | +25.16% | ||
6 months | +21.51% | ||
Current year | +16.11% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 86-12-25 | |
Director of Finance/CFO | - | 12-12-31 | |
B. Adi Reddy
CMP | Compliance Officer | - | 16-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 66 | 86-12-25 | |
Founder | 66 | 86-12-25 | |
Director/Board Member | 64 | 03-05-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.32% | 6 M€ | +6.07% | - | |
0.22% | 21 M€ | +7.49% | ||
0.12% | 11 M€ | +5.41% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-13 | 1,259 | +0.80% | 313 991 |
24-06-12 | 1,249 | -0.64% | 728,599 |
24-06-11 | 1,257 | +0.62% | 659,538 |
24-06-10 | 1,249 | -1.26% | 2,468,196 |
24-06-07 | 1,265 | +1.11% | 1,879,997 |
Delayed Quote NSE India S.E., June 13, 2024 at 04:10 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.11% | 8.77B | |
+48.79% | 781B | |
+41.81% | 639B | |
+19.43% | 330B | |
+7.18% | 293B | |
+17.68% | 248B | |
+0.04% | 221B | |
+11.44% | 217B | |
+4.53% | 162B | |
-3.92% | 157B |
- Stock Market
- Equities
- AUROPHARMA Stock